Latest news from Cell and Gene Therapy Catapult
Click here if you are having trouble viewing this message.
Cell and Gene Therapy Catapult logo
Latest news from CGT Catapult
Spotlight on: Accelerating cell and gene therapy commercialisation
It is at the heart of our mission to accelerate the progression of UK cell and gene therapy companies towards commercialisation. In November, we launched our commercial readiness advice clinics programme, offering SMEs and spin-out companies access to expert, tailored support to evaluate and progress their product towards industrialisation.
The programme aims to further develop the growth of the UK cell and gene therapy industry by supporting the progression of the expanding pipeline of UK companies towards commercial supply. Companies can receive advice to accelerate their development time, de-risk their approach and increase their opportunities of accessing inward investment.

The sixth annual UK GMP manufacturing report and Skills Demand report were released last week showing that cell and gene therapy manufacturing facilities are rapidly becoming operational reflecting job expansion in the sector, with employment in the UK set to more than double by 2024 as more therapies are moving towards commercialisation. The data was presented by Dr Stephen Ward, Chief Manufacturing Officer, at the bioProcess UK conference in Liverpool on 27th November.
Helping cell and gene therapy SMEs and spin-outs accelerate towards commercialisation
Companies can receive 12 hours of tailored support across all stages of commercialisation from process development to non-clinical safety, clinical operations, health economics, regulatory, GMP manufacturing and adoption. Where eligible, the programme is made available to companies with support of the European Regional Development Fund.
Find out more
Investment in UK cell and gene therapy manufacturing set to continue
The sixth annual UK GMP Manufacturing report shows how the manufacturing sector in academia and industry is still growing for the fifth consecutive year and that facilities are rapidly becoming operational. An additional 6,000m2 of manufacturing space is expected to become available in the next 12 months.
Read the release
Tumorigenicity assessment of cell therapy products
Find out more about the challenges, value and future direction of tumorigenicity testing method in this review co-authored by the CGT Catapult Non-clinical Safety team. The article highlights the need for harmonisation of cell therapy product testing from both regulatory and technological perspectives.
Download the open-access article
Accelerated demand for specialist skills in the UK cell and gene therapy industry
Demand for skilled talent is growing at an accelerated pace. The Skills Demand report indicates that the UK cell and gene therapy industry currently supports over 3,000 jobs and this is set to more than double by 2024. The number of manufacturing and bioprocessing roles in particular has tripled in the past two years alone, to over 1,700 roles to date.
Read the release
ISCT webinar: Best practices for designing cell and gene therapy clinical trials
Dr Jacqueline Barry, Chief Clinical Officer, discusses challenges with implementing advanced therapy clinical trials across multiple geographies and interacting with the relevant competent authorities and ethics committees.
Listen to the webinar on demand
Case study: Upgrading digital infrastructure for post-launch evidence generation
The Health Economics and Market Access team have developed a methodological framework for quantifying digital infrastructure upgrade costs in order to address data needs of outcomes-based reimbursement in routine clinical practice.
Read the case study
Did you know?
Find out how we work with companies
Meet the CGT Catapult team
View our full events programme here

Cell Therapy Manufacturing and Gene Therapy Congress 2019
4-6 December, Amsterdam, Netherlands

Anna Outhwaite, Head of ATTC Network Coordination
ATTC Network – Developing robust networks for routine delivery
Friday 6 December, 09.00-10.00

Jahid Hasan, Senior Process Development Scientist
Developing platforms to fulfil robust final fill operation needs
Friday 6 December, 11.00-11.30
Learn more here

Northern Advanced Therapies Network Workshop
9 December, Sheffield, UK

Matthew Durdy, Chief Business Officer
UK ATMP Infrastructure and Support
Tuesday 9 December, 15.30-15.45
Learn more here